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Abstract
Palladin, an actin associated protein, plays a significant role in regulating cell adhesion and cell motility. Palladin is important
for development, as knockdown in mice is embryonic lethal, yet its role in the development of the vasculature is unknown.
We have shown that palladin is essential for the expression of smooth muscle cells (SMC) marker genes and force
development in response to agonist stimulation in palladin deficient SMCs. The goal of the study was to determine the
molecular mechanisms underlying palladin’s ability to regulate the expression of SMC marker genes. Results showed that
palladin expression was rapidly induced in an A404 cell line upon retinoic acid (RA) induced differentiation. Suppression of
palladin expression with siRNAs inhibited the expression of RA induced SMC differentiation genes, SM a-actin (SMA) and
SM22, whereas over-expression of palladin induced SMC gene expression. Chromatin immunoprecipitation assays provided
evidence that palladin bound to SMC genes, whereas co-immunoprecipitation assays also showed binding of palladin to
myocardin related transcription factors (MRTFs). Endogenous palladin was imaged in the nucleus, increased with
leptomycin treatment and the carboxyl-termini of palladin co-localized with MRTFs in the nucleus. Results support a model
wherein palladin contributes to SMC differentiation through regulation of CArG-SRF-MRTF dependent transcription of SMC
marker genes and as previously published, also through actin dynamics. Finally, in E11.5 palladin null mouse embryos, the
expression of SMA and SM22 mRNA and protein is decreased in the vessel wall. Taken together, our findings suggest that
palladin plays a key role in the differentiation of SMCs in the developing vasculature.
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Introduction
Vascular smooth muscle cells (SMCs) are not terminally
differentiated. They have the ability to undergo phenotypic switching
in association with pathological conditions such as vascular injury,
post angioplasty stenosis, and atherosclerosis. Phenotypic plasticity of
SMCs is critical for the establishment of a mature vessel, which can
function to regulate vascular tone and blood vessel diameter,
peripheral resistance, and the distribution of blood flow throughout
the developing organism. Considerable evidence suggests that an
impaired SMC phenotype during development results in defects in
vascular remodeling of great arteries and congenital cardiovascular
anomalies, but a full understanding of the complex processes
underlying SMC development is still elusive.
The differentiation of SMC is characterized by the up-
regulation of SMC marker genes, which are associated with the
contractile phenotype, such as SM alpha actin (SMA), SM myosin
heavy chain (MHC) and SM22. The expression of SMC marker
genes has been shown to be regulated by CArG-SRF complexes,
by myocardin and by Myocardin Related Transcription Factors
MRTF-A and MRTF-B that induce transcription of SMC marker
genes in a CArG dependent manner [1,2,3,4,5]. Other factors,
including Elk-1, Foxo4, and KLF4 [4,5,6,7] have been identified
as repressors for SMC marker gene expression. The actin
cytoskeleton is both an upstream regulator of MRTF activity,
with monomeric (G) actin directly acting as a signal transducer,
and a downstream effector of SRF resulting in activation of cluster
genes encoding components of the actin cytoskeleton [8,9,10].
Actin dynamics plays an important role in regulation of SRF
mediated transcription of SMC marker genes [2,11]. Rho signaling
or other stimuli that promote actin polymerization determine the
availability of G actin. A decrease in the G actin pool is both
necessary and sufficient for SRF to activate expression of SMC
genes. G actin also shuttles into and out of the nucleus, where it is
thought to regulate chromatin structure and transcription[12]. G
actin sequesters MRTFs in the cytoplasm by binding to the MRTF
amino-terminal RPEL domain thereby inhibiting MRTF nuclear
import, nuclear accumulation, and SRF-mediated transcription.
FRET experiments have shown that MRTF and actin interact both
in the cytoplasm and in the nucleus, and that this interaction is the
downstream of RhoA-mediated changes in actin turnover [12].
The actin associated protein palladin is a widely expressed
protein found in stress fibers, focal adhesions, podosomes, dorsal
ruffles, growth cones, Z-discs, and other actin-based subcellular
structures [13]. Palladin is required for the maintenance of normal
stress fibers in cultured cells [14,15]. It belongs to a small gene
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all of which share similar Ig-like domains [13,16,17,18]. Other
palladin family members expressed in skeletal muscle are
important for sarcomere integrity and mutated forms are
associated with inherited muscular disorders [13,19]. Palladin
serves as a scaffold for multiple actin binding proteins, signaling
molecules, and also as an actin cross-linking protein [20].
Knockdown of palladin causes decreased F to G actin ratio, faint
and disordered stress fibers in cultured fibroblasts and SMCs
[15,21,22]. Overexpression of palladin induces strong stress fibers
in cultured cells[23]. Palladin is highly expressed in smooth muscle
and we and others have previously shown it is important in
organization of the SMC cytoskeleton and in regulating
contraction [24,25]. Moreover, we recently published results
showing that palladin knockout embryonic stem cells (ESC) exhibit
impaired differentiation into SMC in a embryoid body (EB) SMC
differentiation model system [26]. Knock out of palladin in mice is
embryonic lethal at day 15.5[27]. However, it is unknown if
palladin KO mice show impaired differentiation of SMC, and little
is known regarding the cellular and molecular mechanisms by
which palladin contributes to control of SMC differentiation.
The present studies focused on determining the role of palladin
in early SMC differentiation and vasculature development. Results
showed that palladin expression was rapidly induced during the
differentiation of SMCs, and induces expression of multiple SMC
differentiation marker genes by interacting with the MRTF
complexes, which directly or indirectly bind to the CArG elements
in the promoter regions of SMC marker genes. Moreover, E11.5
palladin KO mouse embryos exhibited markedly impaired
differentiation of vascular SMC. This study provides the first
evidence that the cytoskeletal protein palladin plays a critical role
in the regulation of early stages of SMC differentiation.
Materials and Methods
We certify that all research using vertebrate animals in the grant
application above is contained in the protocol listed. We certify
that all research using cell lines in the grant application above is
contained in the protocol listed. Protocol entitled ‘‘studies of Signal
Transduction in Smooth and Cardiac Muscles in Genetically
Altered Mice’’ (protocol No 2796) is approved by University of
Virginia animal care and use committee; The protocol title for the
knockout mice is ‘‘Exploring the role of palladin in anterior neural
tube closure,’’ and the number 10-039.0. This protocol is
approved by University of North Carolina at Chapel Hill Animal
care and use committee.
Cell culture, transient transfection and luciferase assay
A404 cells were cultured and induced to differentiate to SMCs
as described previously [26,28]. Wild type, palladin knockout, and
myocardin knockout SMC like cells APSCs (SMA-puromycin-
selected-cells) derived from embryonic stem cells/EBs were
cultured as described previously[26,29]. Transfection of plasmids
was performed with lipofectamine 2000 (Invitrogen, CA) following
the manufacturer’s instruction. Culture of rat aortic SMCs (R518)
were described previously, [24,28]. R518 cells were transfected by
electroporation. For nuclear fractionation, sub confluent R518
cells were treated with 20 and 50 nM of leptomycin B (LMB)
overnight. Nuclear fractionation was carried out according to the
manufacturer’s protocol (Pierece, IL). A404 cells were transfected
with palladin siRNA oligos (Darmacon, NC) using oligofectamine
(Invitrogen, CA) according to the manufacturer’s protocols. Cells
were transfected with 100–300 nM siRNA oligo for 6 h before the
addition of all-trans retinoic acid (RA) (Sigma, MO). KLF4, ACLP
(aortic carboxypeptidase-like protein), SMA and SM22 luciferase
constructs and its CArG mutants were described previously
[30,31,32]. Luciferase activity was measured and normalized to
the total protein content. MRTF RPEL motif mutant constructs
(the mut1 mutated R33A and P34A; the mut2 mutated L39A and
V40A) were made with the QuickChange site directed mutagen-
esis kit according to the supplier’s instructions (Stratagen).
Real-Time RT-PCR
Total RNA was extracted with Trizol regent and cDNA was
generated with a cDNA synthesis kit as previously described.
Quantitative RT-PCR was performed as published [28,29,33]
using specific primers and probes.
In vitro translation and GST pulldown assays
Flag tagged MRTF A/B[30] proteins were translated in TnT
T7 quick coupled transcription/translation system (Promega, WI).
GST tagged palladin and its truncated mutants were described
previously [24]. GST-palladin-glutathione sepharose beads were
incubated with flag tagged MRTF A/B protein for 2 h at 4uC and
washed three times. Bead bound proteins were eluted by boiling
and analyzed with Transcend
TM non-radioactive translation
detection systems following the manufacturer’s instructions
(Promega, WI).
Western blot
Tissues or cultured cells were lysed in RIPA buffer supplement-
ed with 1% of proteinase inhibitor cocktail. The extracts were
cleared at 15,000 g for 10 min at 4uC. Nucleus fractionation was
performed according to the manufacture’s protocol (Pierece, IL).
The equal amounts of protein were subjected to SDS-PAGE.
Western blotting was performed as published methods [24,28].
The sources of antibody used: palladin polyclonal antibody
generated in rabbit recognizes the 140 and 90 kDa palladin
isoforms based on Western blotting, SMA monoclonal antibody
(Sigma, MO), SM22 polyclonal antibody (Abcam, MA), GAPDH
monoclonal antibody (Millipore, MA). All other antibodies are
from Santa Cruz Biotechnology (Santa Cruz, CA). The results
were analyzed on an ODYSSEY infrared imaging system.
ChIP assay
ChIP assays were performed as previously described [32]. A404
cells were treated with RA (1 mmol) for 48 h. A404 and R518 cells
were fixed with 1% formaldehyde for 10 min at 37uC to cross-link
protein-DNA and protein–protein interactions within intact
chromatin. Cells were harvested and sonicated to shear chromatin
fragments to 200–600 base pairs. Chromatin-protein complexes
were immunoprecipitated with antibodies against palladin and
SRF. Salmon sperm DNA and protein A agarose beads were
added to the complexes. Samples were washed and reversibly cross
linked. Recovered DNA was quantified by fluorescence with
picogreen reagent (molecular probes, OR). Real time PCR was
performed to amplify the CArG containing region of the SMA
promoters [32].
Generation of palladin 2/2 mice
See supplemental methods Text S1 and Figure S1.
Indirect Immunofluorescence
Cultured cells were fixed with cold methanol or 4% parafor-
maldehyde and permeabilized with 0.03% Triton X-100 in PBS
rinsed and blocked for 1 h in PBS containing 3% BSA and then
incubated with an anti-myc monoclonal antibody (1:1000), anti-
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antibody (1:200) diluted in blocking solution for 2 h at RT or
overnight at 4uC. Secondary antibodies were Alexa 594
conjugated goat anti-rabbit IgG (1:1000; Molecular Probes) and
Alexa488 goat anti-mouse IgG (1:1000) in blocking buffer (Jackson
ImmunoResearch, PA). Cells were washed four times for 5 min
with PBS before being mounted with Aqua Poly/Mount
(Polysciences, PA). Confocal images were obtained on an Olympus
FV300 microscope.
Immunohistochemistry. Paraffin embedded embryo frontal
sections (5 mm thick) were treated and stained as previous described
[28,34,35]. Primary antibodies were: rabbit anti-palladin polyclonal
antibody (1:1500 dilution), anti-SMA monoclonal antibody
conjugated with alkaline phosphatase (1:800 dilution, Sigma,
Figure 1. the expression of palladin, SMA, and SM22 is induced during SMC differentiation. A. Undifferentiated A404 cells were induced to
differentiate into SMCs by treatment with RA (1 mmol/L). Cells were harvested at different time points, andmRNA was isolated. Palladin andSMC marker
genes SMA, SM22, and smoothelin were quantified with real time RT-PCR, and normalized to ribosomal18s. Values represent the mean 6SEM of three
independent experiments (n=3). # p,0.01; * p,0.05 B. Representative Western blots show that SMA and palladin are induced at the protein level in
A404 cells treated with RA. Undifferentiated subconfluent A404 cells were treated with RA, and cells were lysed with RIPA buffer at different time points.
An equal amount of protein was loaded for SDS-PAGE, and blotted with anti-SMA, palladin, and GAPDH antibodies. The protein expression was
normalized to GAPDH. Quantification of protein expression is showing in the bar graph. Values represent the mean 6SEM (n=3). # p,0.01.
doi:10.1371/journal.pone.0012823.g001
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MA).
Results
Palladin was induced in SMC differentiation model
The importance of palladin in SMC differentiation was
examined in a clonal line of SMC progenitor cells designated
A404 cells [36]. The A404 cells were developed from P19 mouse
embryonic carcinoma cells transfected with a SMA promoter/
puromycin-N-acetyltransferase [36]. This cell line can be induced
to coordinately activate all known SMC differentiation marker
genes by treatment with all-trans retinoic acid (RA) [36]. Results of
the present studies showed a 70-fold increase in mRNA expression
of the 92 kDa isoform of palladin 48 hrs after RA treatment (Fig. 1,
p,0.05). These results are consistent with our previous findings
showing induction of palladin expression within ESC-EBs treated
with RA [26]. In both A404 cells and the ESC-EB model,
following the initial induction of palladin, preceeding SMC marker
gene expression, there was not a direct correlation between the
level of palladin mRNA and SMA mRNA. This may reflect
regulation of mRNA through degradation or translation. On the
other hand, both palladin and SMA protein expression continued
to increase through days 2 through 6.
Palladin is both necessary and sufficient to induce
expression of multiple CArG-dependent SMC marker
genes in A404 progenitor cells
To determine if palladin induces the expression of endogenous
SMC differentiation marker genes, myc tagged palladin expression
constructs were transfected into undifferentiated A404 cells. As
shown in Fig. 2B and 2C, the expression of SMA and SM22 was
significantly increased at both the mRNA level and protein levels.
However, in contrast, there was no induction of the CArG
independent SMC marker gene smoothelin. Induction of CArG-
dependent SMC marker genes required full length palladin as
neither the amino- or carboxyl-terminal deletion mutants of
palladin were effective (Fig. 2C, p,0.01). Conversely, siRNA
induced suppression of palladin was associated with a 70–80%
reduction in SMA and SM22 expression in RA treated A404 cells
(Fig. 2A, p,0.05), but no change in smoothelin expression (data
not shown). This effect is particularly impressive given that the
palladin siRNA only suppressed palladin expression by approxi-
mately 60% in these experiments. Of interest, siRNA induced
suppression of palladin was not associated with any change in
expression of myocardin and MRTFs A and B (data not shown)
indicating effects are not secondary to reduced expression of these
potent CArG-SRF co-activators.
Palladin induced SMC marker genes through CArG-
dependent mechanisms
Transient transfection studies with wild type and CArG mutant
SM22 and SMA promoter-enhancer-luciferase plasmids were
done to determine if palladin induces expression of SMC marker
genes through CArG-dependent mechanisms. Luciferase activity
results showed that palladin induced the transcriptional activity of
wild type SMA and SM22 promoter-enhancer-luciferase con-
structs by 600 and 20-fold respectively in A404 cells (Fig. 3A,
p,0.01). Full-length palladin is necessary for the induction of
SMC marker genes promoter activity, as either amino terminal or
carboxyl terminal half alone cannot induce this activity (Figure 3C,
p,0.01). In contrast, the CArG mutant promoters SMA and
SM22 were not activated as compared to the wild type constructs
(Fig. 3A, p,0.01). These results suggest that palladin-dependent
induction of SMC marker genes was mediated in part through the
CArG-SRF complex. Luciferase reporter assays showed that the
promoter activity of the CArG independent ACLP gene was not
Figure 2. SMA and SM22 genes are down or up regulated by
silencing or overexpression of palladin. A) Undifferentiated A404
cells were transfected with siRNA oligos and then treated with RA for
48 h. The expression of SMA, SM22, and palladin was determined by
real time RT-PCR, and normalized to ribosomal 18s. Values represent the
mean6SEM, n=3. * p,0.05. Inset shows overexpressed palladin was
knocked down with siRNA. B) Undifferentiated A404 cells were
transfected with myc tagged palladin constructs, and cells were
harvested 36 h after transfection. The mRNA expression of SMC marker
genes was measured by real time RT-PCR using specific primers, and
normalized to ribosomal18s. Values represent the mean6SEM (n=3).
#,p,0.01. C) Representative Western blots show that overexpression of
full length, but not the amino (N) or carboxyl (C) terminal halves of
palladin can induce SMA expression. Smoothelin expression was not
changed. Undifferentiated A404 cells were transfected with myc tagged
palladin constructs, and harvested 36 h after transfection. The cell
lysates were loaded for SDS-PAGE, and blotted with anti-SMA, palladin,
and GAPDH antibodies. The protein expression was normalized to
GAPDH.
doi:10.1371/journal.pone.0012823.g002
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(Figure 3B).
Binding of endogenous palladin to the SMA promoter was also
examined in A404 and rat aortic SMCs using ChIP assays. A404
cells were differentiated into SMCs with RA for 48 h, and
harvested for ChIP assays. As shown in Fig. 4, there was marked
enrichment of palladin binding to the endogenous SMA promoter
region in both A404 and R518 cells (p,0.05).
Palladin, MRTF and Myocardin were interdependent in
regulation of SMC genes
The SRF cofactors, myocardin and MRTFs have been shown to
strongly up-regulate a number of SMC marker genes [2,9,33,37] in a
CArG dependent manner. To determine if the effects of palladin on
the SMC marker genes were dependent on these SRF co-activators,
luciferase activity assays were conducted in A404 cells. A404 cells
were co-transfected with palladin+/2 dominant negative myocardin
or MRTF A/B siRNAs, and the wild type SMA promoter luciferase
construct. Suppression ofmyocardin and MRTFs decreased the basal
SMA promoter activity in agreement with previous findings [31,33].
Moreover, silencing of these factors partially attenuated the ability of
palladin to enhance SMA promoter activity (Fig. 5A, p,0.05), in
support of the hypothesis that effects of palladin involve interaction
with these SRF co-activators. This hypothesis was further tested by
comparing the activity of the SMA promoter luciferase construct in
SMC derived from wild type and palladin KO ESCs [26].
Transgenic ESCs were generated that stably expressed a puromy-
cin-resistance gene under the control of a SMA promoter. Negative
selection was then used to purify SMCs from EBs. Purified SMCs
expressing multiple SMC markers were designated APSCs (SMA-
puromycin selected cells) [26]. In this model, the palladin null ESCs
can still differentiate into SMCs based on the selection of SMA
promoter. However, this population of cells has markedly decreased
SMA, SM22, SM MHC, and calponin protein expression. In
luciferasereporterassays,comparedtothewildtypeAPSCs,thebasal
level of SMA and SM22 promoter luciferase activity in palladin
knock out APSCs was significantly decreased (p,0.05, Fig. 5B). The
responses to myocardin, MRTFs, and palladin in both palladin and
myocardin knock out APSCs were significantly decreased compared
Figure 3. Palladin induced SMC marker genes transcription is mediated in part through the CArG elements found within the SM22
and SMA promoters. SM22 and SMA promoter-enhancer-luciferase plasmids were co-transfected with a palladin expression plasmid into
undifferentiated A404 cells. Cells were lysed 36 h after transfection, and luciferase assays were performed and normalized to protein contents. A.
Palladin significantly induces the transcriptional activity of wild type SMA and SM22. Mutation of CArG in SM22 or CArG A (A) and B (B) in the SMA
promoter decreased the response to palladin (p,0.01 compared to wild type; n=3). B) Palladin had no significant effect on the transcriptional
activity of the CArG independent gene, ACLP, while KLF4 activity decreased (n=3, p.0.05). C) Full length palladin, but neither amino (N) or carboxyl
(C) termini of palladin, induced SMC gene transcriptional activity. Values represent the mean6SEM (n=3). #,p ,0.01.
doi:10.1371/journal.pone.0012823.g003
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palladin,myocardinandMRTFsareinter-dependentinregulationof
SMC specific genes.
The carboxyl terminus of palladin bound with MRTF
To determine whether the above results were caused by the
direct interaction of MRTFs, myocardin, SRF and palladin
proteins, co-immunoprecipitation (co-IP) assays were performed.
Myc tagged palladin expression constructs were co-transfected
with flag tagged MRTF-A or MRTF-B into HEK-293 cells. Cells
were lysed 36 h after transfection, and co-IPs were performed with
myc antibody. As shown in Fig. 6A, full length and the carboxyl-
termini of palladin bound to both MRTF-A and –B. However,
there was no detectable palladin interaction with myocardin and
SRF under these experimental conditions (data not shown). The
interaction of palladin with MRTF-A and –B was also confirmed
with an in vitro GST pull down assay (Fig. 6B) using recombinant
GST-palladin and in vitro translated MRTFs. The RPEL domain
of in the amino-terminus of MRTF-A has been shown to be the
critical motif for binding to G actin and for its transcriptional
regulation [38]. We next tested whether the interaction of MRTF
with palladin is via this motif. We mutated the RPEL motif or
truncated its amino terminal 100 amino acids. The mutant
MRTF-A and myc tagged palladin were co-transfected into HEK-
293 cells, and IP was performed with myc antibody. Unexpect-
edly, as shown in Fig. 6C, the amino terminal deletion or the
mutated RPEL of MRTF-A still bound to the full length of
palladin, indicating that other MRTF-A motifs interact with
palladin and that palladin does not compete with actin for the
RPEL domain.
Palladin localized to the nucleus in SMCs
In view of our finding that palladin can greatly induce the
expression of SMC marker genes, we asked whether palladin
shuttles to the nucleus to regulate downstream transcriptional
activity. In order to confirm the role of palladin in differentiated
SMCs, we studied the localization of palladin in rat aortic SMCs
using immunofluorescence assays. We found that endogenous
palladin can be detected in the nucleus of cultured rat aortic SMCs
(Fig. 7A), A404 cells (data not shown), SMCs and endothelial cells
in sections of mouse embryo E11.5 blood vessels, and human
coronary vessels from patients with atherosclerotic disease (Figure
S2). Nuclear localization of palladin also agrees with previously
published results in kidney podocytes (7). Treatment with
leptomycin B leads to a marked increase in endogenous palladin
in the nuclear fraction (Fig. 7D). By overexpression of the amino
and carboxyl terminus of palladin into rat aortic SMCs, we were
able to shown that the carboxyl terminus of palladin localized in
the nucleus, while the amino terminus of palladin localized in the
cytoplasm along actin stress fibers (Fig. 7B). By immuno-
localization assay, we also demonstrated that palladin and
MRTF-A co-localize in the nucleus (Fig. 7C). The finding of
nuclear palladin is consistent with its role in transcriptional
regulation of SMC marker genes.
Expression of SMC specific genes is attenuated in vessels
during embryonic development in palladin null mice
Palladin deficient mice die by day E15.5 and display multiple
defects [22], indicating that palladin plays a critical role in
embryonic development. The palladin null embryos are pale
compared with wild type embryos suggesting poor circulation, an
observation that has been reported previously and attributed to
anemia [22]. However, the effects of KO of palladin on SMC
have not been studied. The expression of SMA and SM22 was
evaluated by immunohistochemistry in frontal sections cut
through the dorsal aorta and associated great vessels of wild
type and palladin null embryos. Neither the pattern of formation
of the great vessels nor the size of the blood vessels in cross section
Figure 4. Chromatin immunoprecipitation assay showing that palladin associates with the SMA promoter in differentiated A404
cells and rat aortic SMCs. A) Schematic structure showing the SMA promoter region amplified in ChIP assay. B) Undifferentiated A404 cells were
differentiated into SMCs with RA. A404 cells were harvested 48 h after RA treatment, and chromatin IP was performed. Subconfluent R518 cells under
normal culture condition were harvested and ChIP assays performed with SRF and palladin antibodies. The intensity of SMA promoter was quantified
with real time PCR. No antibody was used as negative control. Values represent the mean6SEM (n=3). *, p,0.05.
doi:10.1371/journal.pone.0012823.g004
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compared to wild type (data not shown). As shown in Fig. 8A,
the expression of SMA and SM22 was decreased in the dorsal
aorta of palladin knockdown vessels at E11.5. Among the 13
embryos assessed for each group, there were no detectable
differences in muscle cell layer width between wild type and
palladinnullembryosinvesselcross sections.Dueto thedifficulty
in the quantification of staining intensity using immunohisto-
chemistry, Western blotting was used to measure SMA and
SM22 protein content in homogenates from whole embryos of
palladin knockdown and wild type mice (Fig. 8B). There was
approximately a 40–50% decrease of SMA and SM22 protein
expression in palladin knockdown embryos compared to wild
t y p e( F i g .8 C ) .T h i se v a l u a t i o nw as next extended specifically to
blood vessels. We measured the expression of SMA and SM22 at
the mRNA level in umbilical vessels isolated at E11.5. As shown
in Fig. 8D, the mRNA expression of SMA, SM22 and SM MHC
decreased by 70–80% in palladin knockdown vessels (p,0.05)
and by 40–50% in vessels isolated from palladin heterozygous
embryos. It was noted during dissection, that isolated umbilical
vessels from wild type but not palladin null mice contracted
during dissection, consistent with a difference in contractile
protein content. These in situ results suggest that palladin plays a
significant role in the induction of SMC differentiation during
early embryonic development.
Discussion
The actin associated protein, palladin, is a critical structural
component of the actin cytoskeleton, and functions as a molecular
scaffold interacting with multiple proteins in the actin cytoskeleton
[21,24,39,40,41,42]. Palladin exists as multiple isoforms, and the
expression of different isoforms is regulated in a tissue specific
manner, suggesting that different palladin variants may be
specialized for different functions. Cells lacking palladin have
disrupted actin organization and palladin null mice display
defective neural tube and ventral closure leading to embryonic
death [27]. Although it is clear that palladin is required for proper
embryonic development, the role of palladin in the development
and function of the vasculature or its mechanism of action in SMC
is unknown. In the present study, we provide evidence suggesting
that palladin plays an important role in the early stage of SMC
differentiation. We found that palladin induced the expression of
SMC marker genes in vitro using a SMC differentiation model; that
over expression of palladin induced, while down regulation
suppressed the expression of SMC marker genes; that palladin
activated SMC promoter transcriptional activity through CArG
elements by direct or indirect binding to the promoters of SMA or
SM22; that palladin translocates and interacts with MRTFs in the
nucleus; and that the transcriptional activities of palladin and
MRTFs were inter-dependent. Importantly, in palladin deficient
mice, the induction of the SM markers, SMA and SM22 was
significantly attenuated at E 11.5 in whole embryos and in isolated
blood vessels.
The expression of so-called SMC specific markers, such as
SMA, SM22 and SM-MHC, is controlled by multiple transcrip-
tion factors such as SRF and myocardin. Myocardin is exclusively
expressed in SMCs and cardiomyocytes and potently induces the
transcription of CArG containing SMC differentiation marker
genes in the presence of SRF [37]. However myocardin does not
appear to function in the early stage of induction of SMC
differentiation genes, as myocardin null embryonic stem cells were
able to differentiate into SMCs in the context of a chimeric
knockout mouse [43], and the expression of myocardin unlike
Figure 5. Palladin induces SMC marker gene transcription
through the myocardin-MRTF-SRF pathway. A) down regulation
of MRTFs and myocardin attenuates palladin induced SMA activity in
A404 cells. siRNA to MRTFs (siMRTF-A and siMRTF-B) and dominant
negative myocardin (DN Myo) constructs were cotransfected with SMA
promoter luciferase constructs alone or with a palladin expressing
plasmid into A404 cells, and luciferase activities were measured. Values
represent the mean6SEM (n=3). *, p,0.05; # p,0.01. B) SMA and
SM22 promotor transcriptional activities were decreased in palladin null
APSCs. Wild type and palladin null APSCs were transfected with SMA
and SM22 luciferase constructs. Luciferase assays were performed 36 h
after transfection. Values represent the mean6SEM (n=3). *, p,0.05. C)
palladin, myocardin and MRTFs interdependently regulate SMC marker
genes. SMA promoter luciferase construct was cotransfected with
MRTF-A, -B, Myocardin, or palladin expressing plasmids into wild type,
palladin null, and myocardin null APSCs. Luciferase activities were
measured. Values represent mean 6SEM of three independent
experiments. *, p,0.05 compared to WT.
doi:10.1371/journal.pone.0012823.g005
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SMCs [37,44]. These studies suggest that there may be alternative
molecular mechanisms that contribute to the initiation of SMC
differentiation. Palladin presents as early as E8.5 in mice embryos
[45] and it is most highly expressed at 48 h following RA
treatment in A404 (Fig. 1) and at 20 days in EB SMC
differentiation models[26]. This precedes the induction of SMC
marker genes. The induction of SMC marker transcriptional
activity was most significant in undifferentiated A404 cells,
whereas the enhancement is moderate in EB derived SMCs and
adult aortic SMCs (A404...APSCs.=R518). In undifferenti-
ated A404 cells, over-expression of palladin can greatly increase
SMA and SM22 promoter activity 600 and 20 fold respectively,
while in differentiated SMCs APSC and R518 cells the
enhancement is much less. These results suggest that palladin
may be a possible candidate in regulating early stage SMC
differentiation. One possible mechanism for palladin regulation of
expression of SMC marker genes is through MRTFs which are
widely expressed, known to be important in regulating expression
of SMC specific marker genes, and dependent on the Rho family
GTPases and actin dynamics. Palladin’s ability to increase the F:G
actin would free MRTF from cytosolic G actin. In the luciferase
reporter assays, the magnitude of the palladin-enhanced expres-
sion of SMC marker genes was markedly attenuated by down
regulation of MRTFs and/or myocardin in cultured cells (Fig. 5A).
This attenuation was greater when both MRTFs and myocardin
were down regulated than when individually reduced. This
suggests that palladin may function via a SRF-myocardin-MRTF
pathway. By using pull down assays, we showed that the C-
terminus of palladin directly interacts with the C-termini of
MRTFs, which are important for transcriptional activation. This
interaction was also confirmed by over-expression experiments
that showed that the C-terminus of palladin co-localizes with
MRTF-A in the nucleus of rat aortic SMCs and differentiated
A404 cells. Palladin binding to MRTFs in the nucleus may
promote chromatin remodeling and initiate the MRTF-SRF
transcriptional activation of SMCs marker genes. In the reporter
and over expression assays, both N-terminal and C-terminal
halves of palladin are required for the expression of SMC genes.
This plus the fact that the C-terminus of palladin localizes in the
nucleus while the N-terminus localizes in the cytoplasm along
stress fibers, suggests that nuclear and cytoplasmic distribution of
palladin are both necessary for palladin’s function. Whether
palladin interacts with MRTFs in the cytoplasm and then
translocates to nucleus, or they interact in the nucleus is not
known.
Figure 6. Carboxyl terminus of palladin interacts with MRTFs in SMCs. A) Full length, amino (N), or carboxyl (C) terminus of myc tagged
palladin constructs were cotransfected with flag tagged MRTF-A or B into HEK-293 cells. Co-IP assays were performed, and proteins were detected
with myc and flag antibodies. Note that different regions of the gels are shown for full length, and the N- and C-termini, which as expected, run
differently, as shown in Fig. 2C. B) in vitro pull down assays showed that MRTF-A interacts with palladin directly. Recombinant GST tagged palladin
was purified from E.Coli and MRTF-A and –B proteins were translated in vitro. C) MRTF-A interaction with palladin is not via the amino terminal RPEL
domain. The two RPEL motifs (mut1: R33A and P34A and mut2: L39A and V40A) mutants and an amino terminal 100 aa deletion of MRTF-A (DN) were
cotransfected with myc tagged palladin into HEK-293 cells, and co-IP was performed 36 h after transfection with anti-myc antibody and blotted with
anti-myc or flag antibodies.
doi:10.1371/journal.pone.0012823.g006
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PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12823Figure 7. Confocal images demonstrating nuclear localization of full length endogenous palladin and of C terminal but not N
terminal palladin. A) Endogenous palladin was detected in nuclei of mature SMCs (rat aortic SMCs). Cultured subconfluent R518 cells were fixed
with cold methanol and stained with a palladin polyclonal antibody, and with Alexa fluor conjugated secondary anti-rabbit antibody. Inset shows the
Western blot results of palladin in a nuclear fraction. B) Carboxyl (C) terminus of palladin co-localizes with MRTF-A in the nucleus. Rat aortic SMCs
were transfected with myc tagged C-terminus of palladin. The C-terminus of palladin was detected with an anti-myc epitope antibody, and the
endogenous MRTF-A was detected with an anti-MRTF antibody and secondary Alexa fluor conjugated anti-rabbit antibody. C) Expressed carboxyl (C)
terminus but not amino (N) terminus of palladin localizes in the nucleus of R518 cells. Myc tagged N- or C- terminal palladin constructs were
transfected into cultured R518 cells by electroporation. Cells were fixed after 72 h transfection, and proteins were detected with myc antibody.
Secondary antibody labeling alone, under identical conditions showed no detectable fluorescence. Scale bar, 10 mm. D) endogenous palladin was
accumulated in the nucleus by leptomycin B (LMB). Cultured subconfluent R518 cells were trypsinized and subjected to nucleus-cytosolic
fractionation. Equal amounts of protein were loaded for Western bloting. Leptomycin B 20 and 50 nM increased the palladin expression level in the
nucleus fraction. Tubulin was used as a marker for the cytosolic fraction.
doi:10.1371/journal.pone.0012823.g007
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e12823Figure 8. SMA and SM22 expression was attenuated in homogenates of palladin E11.5 knockdown embryos, in isolated umbilical
vessels and in dorsal aortae. A) Representative images show that the expression of SMA and SM22 was attenuated in dorsal aortae at E11.5
embryos by immunohistochemistry analysis. Embryos were fixed and embedded for sectioning. Frontal sections were stained with palladin, SMA, and
SM22 antibodies and corresponding secondary antibodies conjugated with biotin. The signals were developed with DAB and photographed on a
Axioskop 2 Zeiss microscope. Scale bar, 50 mm. B) Western blots showing a significant decrease in the protein expression of SMA and SM22 in
homogenates of whole embryos with its quantification shown in C. The whole embryos were dissected genotyped, and homogenized in RIPA buffer.
An equal amount of protein was loaded for SDS-PAGE, and blotted with SMA, SM22, palladin, SMC specific a-actinin, and GAPDH antibodies. The
signals were normalized to GAPDH. Values represent the mean6SEM (n=3). *, p,0.05. D) The expression of SMA, SM22, and SM MHC mRNA is
markedly decreased in umbilical vessels isolated from E11.5 palladin +/2 and 2/2 mice compared to Wt. Umbilical vessels were dissected from E11.5
wt, het, and knockdown E11.5 embryos. RNA was extracted and SMA, SM22 and SM MHC quantitated by real time RT-PCR. Data was normalized to
18s. Values represent the mean6SEM (n=3). *, p,0.05.
doi:10.1371/journal.pone.0012823.g008
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interact with the promoters of SMC marker genes and initiate
transcription of SMC marker genes. We showed that mutation of
CArG elements in the SMC gene promoters significantly
decreased the responses to palladin (Fig. 2). In addition, we found
that palladin can bind to the SMA promoter within intact
chromatin by ChIP assays (Fig. 4). Thus, it is also possible that
palladin can shuttle to the nucleus and directly bind to SMC gene
promoters to modulate chromatin structure and regulate tran-
scription of SMC marker genes. We detected endogenous palladin
in the nuclei of SMCs. We favor the hypothesis that palladin
regulates SMC differentiation through both direct and indirect
pathways. The possible mechanisms whereby palladin regulates
SMC markers are illustrated in Fig. 9. On the one hand, palladin
released from the cytoskeleton can translocate to the nucleus and
regulate transcription either by binding directly to the promoters
of SMC marker genes or by forming a complex with MRTFs and
SRF to enhance transcription. In addition palladin’s regulation of
actin dynamics frees cytosolic MRTFs, which translocate to the
nucleus to further enhance transcription of SMC marker genes.
Palladin deficient mice die by day E15.5 and display multiple
defects including defective cranial neural tube closure and fetal
liver herniation indicating that palladin plays a critical role in
embryonic development. The exact mechanism whereby palladin
knockout leads to embryonic lethality remains unclear and the
importance of palladin in the development of the vasculature is not
clear. However, results of the present studies provide clear
evidence that palladin plays an important role in SMC
differentiation in in vitro model systems. Moreover, consistent with
these results, palladin knockdown embryos E11.5 showed
decreased expression of SMA and SM22 protein in the dorsal
aorta by immunohistochemstry analysis and in whole embryos by
Western blotting (Fig. 8). Finally, a dramatic reduction in SMA,
SMA and SM MHC mRNA was found in isolated umbilical
vessels at E11.5 (Fig. 8). However, as no visible changes were
observed in either the pattern or size of the great vessels or the
umbilical vessels, palladin does not appear to contribute to the
mechanisms underlying those processes at least at the E11.5 time
point. In view of the partial expression of SMA and SM22 in the
palladin knockdown vessels, palladin is either not absolutely
required for their expression or compensatory mechanisms have
been turned on. The decreased expression of the SMC markers at
the protein level, in the palladin null embryos is consistent with our
earlier finding of decreased force development in palladin null
SMCs isolated from EBs. This repressed contractility of the
vasculature likely contributes to the palladin null embryonic
Figure 9. Scheme showing possible mechanisms whereby palladin regulates SMC differentiation. Palladin released from the
cytoskeleton can translocate to the nucleus and regulate transcription either by binding directly to the promoters of SMC marker genes or by forming
a complex with MRTFs and SRF or their associated proteins. In addition palladin’s regulation of actin dynamics frees cytosolic MRTFs, from G actin
which translocate to the nucleus to further enhance transcription of SMC marker genes.
doi:10.1371/journal.pone.0012823.g009
Palladin Regulates SMC Genes
PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12823lethality due to the weakened vessel walls. The death of the
embryos at about E15.5 corresponds to the time when the
coronary circulation is perfused as it connects to the aorta.
Taken together, our findings demonstrate that palladin plays a
key role, through both direct and indirect pathways, in the
induction of SMC marker genes during the early stages of SMC
differentiation. Further studies are needed to determine mecha-
nisms by which palladin promotes transcriptional activation
through binding to SMC promoters, and what genes may
compensate, at least in part, for its loss.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0012823.s001 (0.02 MB
DOCX)
Figure S1 Disruption of palladin in mice. A. Construct design
for palladin gene disruption. See details in Experimental
procedures. B. PCR analysis of genomic DNA from yolk sac of
10.5 dpc embryos derived from palladin+/2 mouse intercrossing.
C. Southern blot analysis. Several PCR-positive clonal DNA
samples were digested with XhoI and NdeI and southern blotted.
The detection of a 4.9 kb band indicates that the vector DNA has
recombined at the correct site, introducing a novel XhoI site into
the allele. D. Protein immunoblot analysis of mouse embryonic
tissue from a heterozygote intercross. Palladin was identified with
the monoclonal Ab 1E6 (1,2). WT, wild type; HET, heterozygote;
KO, knockout. Same blot was reprobed with tubulin Ab for
loading control.
Found at: doi:10.1371/journal.pone.0012823.s002 (0.09 MB
TIF)
Figure S2 Palladin localized to SMC and endothelial cell nuclei
in human coronary vessels with atherosclerosis (upper panels) and
in wild type but not palladin null mouse embryonic blood vessels
(E11.5) (lower panels). Nuclear palladin was not present in all cells
showing cytoplasmic palladin staining and may reflect different
states of differentiation. Sections from fixed human coronary
vessels and frontal sections from fixed and embedded embryos
were stained with palladin antibody which one (we did not
mention different antibodies in the text) and a anti-rabbit antibody
conjugated with biotin. Signals were developed with DAB and
photographed on a Axioskop 2 Zeiss microscope. scale bar:
10 mm.
Found at: doi:10.1371/journal.pone.0012823.s003 (25.24 MB
TIF)
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